Acadia Pharmaceuticals stock price target maintained by BMO after trial miss
NegativeFinancial Markets

Acadia Pharmaceuticals faced a setback as BMO maintained its stock price target following a disappointing trial outcome. This news is significant for investors as it reflects ongoing challenges for the company in achieving its developmental goals, potentially impacting its market performance and investor confidence.
— Curated by the World Pulse Now AI Editorial System